Search company, investor...



Unattributed - II | Alive

Total Raised


Last Raised

$18M | 12 yrs ago

About OrSense

OrSense provides non-invasive monitoring of various blood constituencies.

Headquarters Location

5 Golda Meir St Weizmann Science Park, P.O.Box 4052




Missing: OrSense's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: OrSense's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing OrSense

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

OrSense is included in 1 Expert Collection, including Medical Devices.


Medical Devices

3,088 items

Companies that have been granted at least 1 510(k) by the FDA since 2014. Companies tagged as #FDA510(K)

OrSense Patents

OrSense has filed 1 patent.

patents chart

Application Date

Grant Date


Related Topics




Spectroscopy, Sensors, Optical devices, Polarization (waves), Quantum mechanics


Application Date


Grant Date



Related Topics

Spectroscopy, Sensors, Optical devices, Polarization (waves), Quantum mechanics



Latest OrSense News

Continous Blood Glucose Monitoring Global Market Report 2022

Jun 15, 2022

2022" - , AgaMatrix Inc., B. Braun Melsungen, Ypsomed Holding AG, Terumo, and Orsense ltd. The global continuous blood glucose monitoring market is expected to grow from $9.94 billion in 2021 to $11.12 billion in 2022 at a compound annual growth rate (CAGR) of 11.9%. The continuous blood glucose monitorin market is expected to reach $16.29 billion in 2026 at a CAGR of 10%. The continuous blood glucose monitoring market consists of sales of continuous blood glucose monitoring devices by entities (organizations, sole traders, and partnerships), that are used to track and monitor glucose levels in the blood. A continuous blood glucose monitoring device enables a person to better regulate glucose levels throughout the day and to experience fewer low blood glucose situations. The main types of components in continuous blood glucose monitoring devices are insulin pumps, sensors, transmitters, and receivers.Insulin pumps are small, computerized devices designed and programmed to deliver pre-determined doses of insulin in diabetic patients at specific intervals. These devices are used by type 1 diabetic patients, type 2 diabetic patients, gestational diabetes, and critical care patients which are used by various end-users including hospitals, homecare diagnostics, and other end users. North America was the largest region in the continuous blood glucose monitoring market in 2021. The regions covered in the continuous blood glucose monitoring market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The increasing prevalence of diabetes is expected to propel the growth of the continuous blood glucose monitoring market going forward.Diabetes is a health disease that occurs when the blood glucose levels fluctuate in the body. Blood glucose monitoring devices can aid in the detection of trends and patterns that give a better full picture of a diabetic’s condition. For instance, according to the International Diabetes Federation, in 2020 around 463 million adults were affected by diabetes among which 10.0% of them had type 1 diabetes and 90.0% had type 2 diabetes. Therefore, the increasing prevalence of diabetes is driving the growth of the continuous blood glucose monitoring market. Technological advancements have emerged as a key trend gaining popularity in the continuous blood glucose monitoring market.Major companies operating in the continuous blood glucose monitoring market are focused on developing advanced technological solutions to strengthen their position in the market. For instance, in 2020, Philips, a Netherlands-based health technology company that manufactures glucose monitoring devices launched non-invasive monitors for COPD patients based on ExpiraFlow technology. The non-invasive monitors help health care professionals to detect and screen the expiratory flow limitation and can also be used in optimal home care therapy. In August 2020, Medtronic Plc, an Ireland-based medical device company acquired Companion Medical for an undisclosed amount.The acquisition is intended to allow Medtronic Plc to extend its product line and provide people with a one-of-a-kind and expansive ecosystem of support for their diabetes. Companion Medical Inc. is a US-based company that manufactures smart insulin pens which are used to monitor blood glucose. The countries covered in the continuous blood glucose monitoring market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA.

OrSense Web Traffic

Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

OrSense Rank

OrSense Frequently Asked Questions (FAQ)

  • What is OrSense's latest funding round?

    OrSense's latest funding round is Unattributed - II.

  • How much did OrSense raise?

    OrSense raised a total of $24M.

  • Who are the investors of OrSense?

    Investors of OrSense include Star Ventures, Israel Healthcare Ventures, IHCV and Blue Coast Capital.

  • Who are OrSense's competitors?

    Competitors of OrSense include Endotronix, Cyberheart, Ornim Medical, ASL Analytical, Silicon Biosystems and 11 more.

Compare OrSense to Competitors


Biopeaks vision is to develop leading edge non-invasive blood analysis devices.  The company's early research focused on lactic acid analysis for the performance athletic market.  As technical results and market information, the company contends that Biopeaks technology was ideal for other larger markets including glucose monitoring. Biopeak is now actively developing a noninvasive glucose analyzer based on its Fusion Spectroscopy technology platform.


InnerPulse develops minimally invasive devices for cardiac rhythm management

Ornim Medical Logo
Ornim Medical

Ornim specializes in clinical research, development, and distribution of the highest quality medical devices in the field of tissue and cerebral blood flow and perfusion. The Company's leading product, the c-FLOW, is a bedside patient monitor based on the patented UTLight technology that provides physicians with unique monitoring solutions, revolutionizing individualized and personalized patient care.

TruTouch Technologies

TruTouch Technologies develops, manufactures and sells non-invasive alcohol intoxication and biometric testing systems which provide companies with an effective deterrent system available for unobtrusive verification of sobriety on a daily or routine basis. Inspired by the potential to place its passive, durable systems virtually anywhere, TruTouch's vision is to create a world where intoxication is routinely intercepted before it does harm.


Suquenshal is a semi-non-invasive surgical tool used to identify and eliminate cardiac arrhythmias including atrial fibrillation.

Pro-Duct Health

Pro-Duct Health is a medical device company focused on developing and commercializing products for non-invasive detection of breast cancer.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.